-+ 0.00%
-+ 0.00%
-+ 0.00%

POVOFORTAY® (POVORCITINIB) APPROVED IN EUROPE AS THE FIRST ONCE-DAILY ORAL TREATMENT FOR ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

Reuters·11/16/2026 21:30:00

Please log in to view news